 |
Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care
SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative applications of AI in cancer research. This collaboration aims to advance research into the tumor microenvironment and immune phenotyping, analyzing NCI data to uncover insights that could drive personalized cancer care.
Under the agreement, Lunit tools will be made available to NCI Center for Cancer Research (CCR) investigators, across NCI CCR's portfolio of clinical trials. Lunit will analyze whole-slide images obtained from NCI's clinical studies, using Lunit AI-powered biomarker technologies, including Lunit SCOPE® IO and Lunit SCOPE universal IHC. This broad collaboration will enable image-analysis AI to become a core part of cancer research practice.
The two parties plan to jointly prepare publications, presentations, and reports. The primary objective of this partnership is to develop data-driven insights that can help personalize treatment approaches for cancer patients. By applying Lunit's AI solutions across NCI's extensive cancer research portfolio, the collaboration seeks to accelerate discoveries that optimize immunotherapy strategies, improve patient outcomes, and pave the way for more targeted cancer care.
"This collaboration with the NCI is a testament to the power and potential of Lunit's AI-driven solutions in advancing the frontier of cancer research," said Brandon Suh, CEO of Lunit. "By applying our technologies across NCI's unparalleled research expertise and clinical data, we aim to uncover meaningful insights that can transform cancer treatment and deliver more personalized care to patients worldwide. We are honored to work with one of the world's leading cancer research institutions to tackle some of the toughest challenges in oncology."
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer through AI. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.
Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care
SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics, today announced a collaboration with the National Cancer Institute (NCI), part of the U.S. National Institutes of Health (NIH), to explore innovative applications of AI in cancer research. This collaboration aims to advance research into the tumor microenvironment and immune phenotyping, analyzing NCI data to uncover insights that could drive personalized cancer care.
Under the agreement, Lunit tools will be made available to NCI Center for Cancer Research (CCR) investigators, across NCI CCR's portfolio of clinical trials. Lunit will analyze whole-slide images obtained from NCI's clinical studies, using Lunit AI-powered biomarker technologies, including Lunit SCOPE® IO and Lunit SCOPE universal IHC. This broad collaboration will enable image-analysis AI to become a core part of cancer research practice.
The two parties plan to jointly prepare publications, presentations, and reports. The primary objective of this partnership is to develop data-driven insights that can help personalize treatment approaches for cancer patients. By applying Lunit's AI solutions across NCI's extensive cancer research portfolio, the collaboration seeks to accelerate discoveries that optimize immunotherapy strategies, improve patient outcomes, and pave the way for more targeted cancer care.
"This collaboration with the NCI is a testament to the power and potential of Lunit's AI-driven solutions in advancing the frontier of cancer research," said Brandon Suh, CEO of Lunit. "By applying our technologies across NCI's unparalleled research expertise and clinical data, we aim to uncover meaningful insights that can transform cancer treatment and deliver more personalized care to patients worldwide. We are honored to work with one of the world's leading cancer research institutions to tackle some of the toughest challenges in oncology."
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a medical AI company on a mission to conquer cancer through AI. Lunit harnesses AI-powered medical image analytics and biomarker analysis to ensure accurate diagnosis and optimal treatment for each cancer patient. The FDA-cleared Lunit INSIGHT suite for cancer screening serves over 4,800 medical institutions across 55+ countries. Lunit clinical studies have been published in top journals, including the Journal of Clinical Oncology and the Lancet Digital Health, and presented at global conferences such as the ASCO and RSNA. Headquartered in Seoul, South Korea, with a network of offices worldwide, Lunit leads the global fight against cancer. Discover more at lunit.io.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research
NEW YORK, April 20, 2026 /PRNewswire/ -- Saramonic, a leading brand in audio solutions, announced a 9-Person Modular Full-Duplex Wireless Intercom System WiTalk9 X and the WiTalk9 Base. WiTalk9 X builds upon the success of the WiTalk9 with a focus on lightweight comfort and modular adaptability, introducing unprecedented flexibility and scalability of modern production teams from small to large.
Industry-First Modular Design for Maximum Flexibility
The Saramonic WiTalk9 X sets a new standard for adaptability in wireless intercom systems. Its industry-first modular construction allows users to switch between single-ear, dual-ear, or helmet-ready models, accommodating the diverse needs of different crew roles.
Weighing just 172 grams (6 oz) with battery in its single ear configuration, the WiTalk9 X delivers all-day comfort for demanding production environments. The IPX4-rated, lightweight design allows professionals who wear headsets for extended periods during long shoots or live events to focus on their work.
Intelligible Voice Communication: Saramonic ClearTalk™2.0 Technology and AI Noise Cancellation
Saramonic ClearTalk™2.0 combines the dual-microphone array and Saramonic AI Noise Cancellation. The cardioid main microphone focuses on the speaker's voice, and the omnidirectional secondary mic collects the noise as samples for Saramonic AI Noise cancellation to separate the vocal and noise, ensuring clear and stable voice communication.
Saramonic AI Noise Cancellation is trained by over 700,000 noise samples across 20,000+ hours. Compared to traditional environmental noise cancellation that only handles ambient sounds, it identifies and separates noise in real-time to keep voice clear and stable within team communication, even when multiple crews speak at once in a complex environment.
Efficient Team Work with Dual-Antenna Design and Saramonic WiTalk Wireless Intercom Ecosystem
The WiTalk9 X features both internal and external antennas to continuously monitor signal quality and select the stronger signal. It operates on the 1.9 GHz DECT Technology and offers up to 12 hours battery life with a spare rechargeable lithium battery for quick replacement, enables teams to stay connected within 1,300 ft (400m) - ideal for events, film shoots, and live performances.
Saramonic WiTalk9 X supports a 9-person system without a hub, and can be easily scaled up to 64 users via WiTalk Base, enabling group cascading and remote collaboration with an industry-leading range of up to 700 meters.
Pricing and Availability
The Saramonic WiTalk9 X is available through official stores. For detailed pricing and configuration options, please contact your local Saramonic representative or visit www.saramonic.com.
Contact: marketing@saramonic.com
** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **
Saramonic WiTalk9 X: Modular-Designed, Lightweight Wireless Intercom System Redefines Team Communication
